Clonidine for treating patients with mild hypertension and angina pectoris

  • T. Zaleska
  • L. Ceremużyński


An increase in the activity of the adrenergic nervous system is one of the features of mild hypertension and is thought to contribute to the mechanism of the disease (De Quatro and Chan 1972; Champlain et al. 1981). Both hypertension and augmented sympathetic drive help to produce the symptoms of angina pectoris by increasing af-terload and accelerating metabolic rate, respectively. Each of these mechanisms raises the oxygen demand of the heart muscle and is likely to lead to a shortage of oxygen, which is known to trigger coronary pain.


Angina Pectoris Mild Hypertension Double Product Chronic Angina Pathetic Nervous System 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Ceremuzyński L, Łada J, Maruchin M, Dluzniewski M, Herbaczyńska-Cedro K (1979 a) Suppression of catecholamine excretion by low doses of Clonidine in healthy subjects and feasibility study on Clonidine application in angina pectoris. Drug Res 5:829–835.Google Scholar
  2. 2.
    Ceremuzyński L, Zaleska T, Łada W, Zalewski A (1979 b) Clonidine effect in chronic angina pectoris. Double-blind, crossover trial on 60 patients. Eur J Cardiol 10:415–427.PubMedGoogle Scholar
  3. 3.
    Challoner DR, Steinberg D (1966) Oxidative metabolism of myocardium as influenced by fatty acids and epinephrine. Am J Physiol 211:897–902.Google Scholar
  4. 4.
    Champlain J, Cousineau D, Lapointe L, Lavalee M, Nadean R, Denis G (1981) Sympathetic abnormalities in human hypertension. Clin Exp Hypertension 3:417–438.CrossRefGoogle Scholar
  5. 5.
    De Quattro V, Chan S (1972) Raised plasma catecholamines in some patients with primary hypertension. Lancet i: 806–809.CrossRefGoogle Scholar
  6. 6.
    Finney DJ, Latscha R, Benett BM, Hsu P (1963) Tables for testing significance in a 2x2 contingency table. Cambridge University Press, Cambridge.Google Scholar
  7. 7.
    Górny D (1964) Fluorimetric determination of free adrenaline and noradrenaline in urine (in Polish). Pol Tyg Lek 19:632–635.PubMedGoogle Scholar
  8. 8.
    Kobinger W, Walland A (1967) Investigations into the mechanisms of the hypotensive effect of 2-(2,6-dichlorophenylamino)-2-imidazoline HCI. Eur J Pharmacol 2:155–162.PubMedCrossRefGoogle Scholar
  9. 9.
    Mueller HS, Ayres SM (1978) Metabolic responses of the heart in acute myocardial infarction in man. Am J Cardiol 42:363–371.PubMedCrossRefGoogle Scholar
  10. 10.
    Raab W (1963) The nonvascular metabolic myocardial vulnerability factor in “coronary heart disease”. Am Heart J 66:685–706.PubMedCrossRefGoogle Scholar
  11. 11.
    Schmitt H, Schmitt H, Boissier JR, Giudicelli JF (1967) Centrally mediated decrease in sympathetic tone induced by 2-(2,6-dichlorophenylamino)-2-imidazoline (ST 155, Catapresan). Eur J Pharmacol 2:147–148.PubMedCrossRefGoogle Scholar
  12. 12.
    von Euler US, Lishajko F (1959) The estimation of catecholamines in urine. Acta Physiol Scand 45:122–132.CrossRefGoogle Scholar

Copyright information

© Dr. Dietrich Steinkopff Verlag, GmbH & Co. KG, Darmstadt 1984

Authors and Affiliations

  • T. Zaleska
  • L. Ceremużyński
    • 1
  1. 1.Department of Cardiology, Postgraduate Medical SchoolGrochowski HospitalWarsawPoland

Personalised recommendations